Compare LCFY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCFY | BIAF |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.2M |
| IPO Year | 2021 | 2022 |
| Metric | LCFY | BIAF |
|---|---|---|
| Price | $2.47 | $7.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 7.0M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,900,000.00 |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $2.10 | $0.33 |
| 52 Week High | $7.67 | $20.35 |
| Indicator | LCFY | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 53.42 |
| Support Level | $2.50 | $1.07 |
| Resistance Level | $2.73 | $12.48 |
| Average True Range (ATR) | 0.16 | 1.56 |
| MACD | 0.03 | -0.37 |
| Stochastic Oscillator | 68.64 | 28.16 |
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.